Akebia Therapeutics Stock Analysis
Technical stock analysis for 18 January 2019
Akebia Therapeutics gained 1.43% in the last trading day, rising from $6.30 to $6.39 , and has now gained 5 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. The price has risen in 6 of the last 10 days and is up by 5.79% over the past 2 weeks. Volume has increased in the last day along with the price, which is a positive technical sign, and, in total, 245 088 more shares were traded than the day before. In total, 624 978 shares bought and sold for approximately $3.99 million.
Close price at the end of the last trading day (Friday, 18th Jan 2019) of the AKBA stock was $6.39. This is 1.43% more than the trading day before Thursday, 17th Jan 2019.
During day the stock fluctuated 5.99% from a day low at $6.18 to a day high of $6.55.
30 day high of the AKBA stock price was $6.98 and low was $5.20.
90 day high was $10.45 and low was $5.20.
52 week high for the Akebia Therapeutics - $15.78 and low - $5.20.
Akebia Therapeutics lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -23.18% during the next 3 months and, with 90% probability hold a price between $3.61 and $6.23 at the end of this period.
A buy signal was issued from a pivot bottom point on Monday January 14, 2019, which indicates further gains until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. Akebia Therapeutics holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $6.88. On a fall, the stock will find some support from the short-term average at $6.23. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sales signal and strengthen the general signal.
Relative Strength Index (RSI)
The stock holds a RSI14 at 71 and is currently being overbought on RSI. This does not have to be a sales signal as many stocks may go both long and hard while being overbought on the RSI. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness.
Support & Resistance
On the downside, the stock finds support just below today's level from accumulated volume at $6.04 and $5.53.
There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Akebia Therapeutics finds support just below today's level at $6.04. If this is broken, then the next support from accumulated volume will be at $5.53 and $5.42.
This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.37 between high and low, or 5.99%. For the last week, the stock has had a daily average volatility of 4.28%.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
Very Low Low Medium High Very High
Akebia Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
|AKBA $6.39 $0.09(1.43%)|
AKBA is up $0.09 today, but where's it headed in 2019?
|Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month system that more than doubles the S&P 500.
Click here – the AKBA analysis is free »